[
  {
    "ts": null,
    "headline": "Amgen Inc. (AMGN) BofA Securities 2025 Healthcare Conference (Transcript)",
    "summary": "Amgen Inc. (NASDAQ:AMGN) BofA Securities 2025 Healthcare Conference Call May 14, 2025 12:20 PM ETCompany ParticipantsPeter Griffith - Executive Vice...",
    "url": "https://finnhub.io/api/news?id=d78c8a2c2dfe47ebe605fe583a8af4142dc8a650682e47b8027c93502946eee6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747239682,
      "headline": "Amgen Inc. (AMGN) BofA Securities 2025 Healthcare Conference (Transcript)",
      "id": 134453599,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Amgen Inc. (NASDAQ:AMGN) BofA Securities 2025 Healthcare Conference Call May 14, 2025 12:20 PM ETCompany ParticipantsPeter Griffith - Executive Vice...",
      "url": "https://finnhub.io/api/news?id=d78c8a2c2dfe47ebe605fe583a8af4142dc8a650682e47b8027c93502946eee6"
    }
  },
  {
    "ts": null,
    "headline": "BlackRock Health Sciences Opportunities Fund Q1 2025 Commentary",
    "summary": "BlackRock Health Sciences Opportunities Fund posted returns of 3.66% (Institutional shares) and 3.60% (Investor A shares, without sales charge) for the first quarter of 2025.",
    "url": "https://finnhub.io/api/news?id=a09fa1031198fe3423a5318e0d47459c521efb03ae4196a089069f85176f0e54",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747237080,
      "headline": "BlackRock Health Sciences Opportunities Fund Q1 2025 Commentary",
      "id": 134453013,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/183355336/image_183355336.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "BlackRock Health Sciences Opportunities Fund posted returns of 3.66% (Institutional shares) and 3.60% (Investor A shares, without sales charge) for the first quarter of 2025.",
      "url": "https://finnhub.io/api/news?id=a09fa1031198fe3423a5318e0d47459c521efb03ae4196a089069f85176f0e54"
    }
  },
  {
    "ts": null,
    "headline": "Dow's 115-point drop led by losses for Amgen, 3M stocks",
    "summary": "Dow's 115-point drop led by losses for Amgen, 3M stocks",
    "url": "https://finnhub.io/api/news?id=fe994dfedeced3bae800e6590a04318330ed9fec1d3b55e456f1986dc367eb7e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747220700,
      "headline": "Dow's 115-point drop led by losses for Amgen, 3M stocks",
      "id": 134437978,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Dow's 115-point drop led by losses for Amgen, 3M stocks",
      "url": "https://finnhub.io/api/news?id=fe994dfedeced3bae800e6590a04318330ed9fec1d3b55e456f1986dc367eb7e"
    }
  },
  {
    "ts": null,
    "headline": "A Path To Antibody Protection",
    "summary": "In the wake of the 2023 Supreme Court's decision in Amgen, Inc. v Sanofi, the remaining means by which patent practitioners can claim antibodies while satisfying the requirements of 35 U.S.C. § 112...",
    "url": "https://finnhub.io/api/news?id=5029aff2c8e4f1162391f3db0cfa9082bcd8d23b92cdc7f7cac58e229d6d0edb",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747217716,
      "headline": "A Path To Antibody Protection",
      "id": 134436049,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "In the wake of the 2023 Supreme Court's decision in Amgen, Inc. v Sanofi, the remaining means by which patent practitioners can claim antibodies while satisfying the requirements of 35 U.S.C. § 112...",
      "url": "https://finnhub.io/api/news?id=5029aff2c8e4f1162391f3db0cfa9082bcd8d23b92cdc7f7cac58e229d6d0edb"
    }
  },
  {
    "ts": null,
    "headline": "BBH: Fear Of Price Controls Is Not The Problem",
    "summary": "The VanEck Biotech ETF offers lower risk with established companies, but 23% of AUM in speculative stocks poses a risk. Check out why I rate BBH a sell.",
    "url": "https://finnhub.io/api/news?id=5b9b2ebe607eb4d37afae12d3df292c9ef9d6c96c54e06f280d50c128a84afe4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747213200,
      "headline": "BBH: Fear Of Price Controls Is Not The Problem",
      "id": 134435713,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2200850893/image_2200850893.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "The VanEck Biotech ETF offers lower risk with established companies, but 23% of AUM in speculative stocks poses a risk. Check out why I rate BBH a sell.",
      "url": "https://finnhub.io/api/news?id=5b9b2ebe607eb4d37afae12d3df292c9ef9d6c96c54e06f280d50c128a84afe4"
    }
  },
  {
    "ts": null,
    "headline": "3 Healthcare Stocks to Research Further",
    "summary": "Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 8%. This drawdown was worse than the S&P 500’s 1% fall.",
    "url": "https://finnhub.io/api/news?id=71e122e66d2d9009b27d8b09ace3360330f4f8a0645406bb16483a6eef26cd8d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747197198,
      "headline": "3 Healthcare Stocks to Research Further",
      "id": 134461018,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 8%. This drawdown was worse than the S&P 500’s 1% fall.",
      "url": "https://finnhub.io/api/news?id=71e122e66d2d9009b27d8b09ace3360330f4f8a0645406bb16483a6eef26cd8d"
    }
  }
]